double-blind, placebo-controlled, parallel-group study (Kemp JP, Skoner D, Szefler SJ, et al. Ann Allergy Asthma Immunol. 1999;83:231-239). This study retrospectively examines the data more closely and demonstrates that efficacy and safety are not dependent on whether administration is by facemask or mouthpiece. The results here provide reassuring data for clinicians treating children with persistent asthma who are too young to use mouthpieces. Similar results have also been reported for children in this age group with moderate persistent asthma (Mellon M, Leflelin J, Walton-Bowen K, et al.
2 received oral methylprednisolone (1 mg/kg/day) plus inhaled budesonide (800 g daily) plus dry powder terbutaline (2000 g daily). Both groups were evaluated before treatment and 4 days after 3 complete days of treatment. Pre-and posttreatment pulmonary index scores, forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC), FEV 1 /FVC and forced expiratory flow 25%-75% (FEF 25%-75% ) were evaluated. Pulmonary index scoring (PIS) evaluated the physical examination findings of respiratory rate, severity of wheezing, inspiration/expiration ratio, and the use of accessory muscles.
Results. Thirty-one patients were in the high-dose budesonide group and 29 were in the methylprednisolone group. There were no significant differences in the demographics of the 2 groups, including such characteristics as age of disease onset, mean number of acute attacks in previous year and duration of symptoms at presentation. There were no significant differences between the 2 groups with respect to baseline PIS, FEV 1 , FEV 1 /FVC, or FEF 25%-75% . A statistically significant decrease in PIS and a statistically significant increase in FEV 1 , FEV 1 /FVC, or FEF 25%-75% were detected in both groups after 4 days of treatment. Comparison of the 2 groups revealed that the mean decrease in the PIS was 2.61 Ϯ 1.12 in the group receiving high-dose budesonide and 1.90 Ϯ 1.08 in the group receiving oral steroids (P ϭ .038). No statistically significant differences were detected between the 2 groups with respect to the increase in lung function measurements (FEV 1 , FEV 1 /FVC, or FEF 25%-75% ). None of the patients who had received high-dose budesonide required treatment with oral steroids. During the follow-up period, 3 patients in the high-dose budesonide group and 8 patients in the oral steroids group needed to continue their therapy for 2 additional days because of incomplete recovery.
Conclusion. Short-term high-dose budesonide therapy can be considered as an alternative for children who are experiencing an acute asthma attack that is unresponsive to home management with regular use of inhaled ␤ 2 -agonist, yet who are not severe enough to hospitalize.
Reviewer's Comments. This study supports an earlier study that demonstrated that high-dose budesonide was as effective as oral prednisolone over a 1 week period. An interesting finding in this shorter study is that with respect to clinical improvement, high-dose budesonide may be more effective than oral steroids plus medium-dose budesonide. Parents are extremely concerned about the use of steroids and the use of high-dose inhaled for mild exacerbations instead of oral steroids will most likely be wellreceived. This study is on the right track for future therapeutic options, although it should be noted that these patients only had mild exacerbations and that the results cannot necessarily be extrapolated to more severe episodes.
